Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.
about
Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiformeCurrent standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patientsAdaptation to antiangiogenic therapy in neurological tumorsPhospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapyRetinal upregulation of inflammatory and proangiogenic markers in a model of neonatal diabetic rats fed on a high-fat-diet.MicroRNA-326 functions as a tumor suppressor in glioma by targeting the Nin one binding protein (NOB1)Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience.Distribution and quantification of irinotecan and its active metabolite SN-38 in colon cancer murine model systems using MALDI MSI.Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trialResponse assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria.Antiangiogenic therapy for glioma.The diagnostic performance of perfusion MRI for differentiating glioma recurrence from pseudoprogression: A meta-analysis.Improved Treatment Efficacy of Antiangiogenic Therapy when Combined with Picornavirus Vaccination in the GL261 Glioma Model.Treatment of recurrent diffuse intrinsic pontine glioma: the MD Anderson Cancer Center experience.Irinotecan and bevacizumab in recurrent glioblastoma multiforme.The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review.Implication of tumor microenvironment in chemoresistance: tumor-associated stromal cells protect tumor cells from cell death.Recent advances in targeted therapy for glioblastoma.Direct effect of bevacizumab on glioblastoma cell lines in vitro.HMGN5: a potential oncogene in gliomas.Human umbilical vein endothelial cell vaccine therapy in patients with recurrent glioblastoma.Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis.MRI tumor response and clinical outcomes after LINAC radiosurgery on 50 patients with recurrent malignant gliomas.Localized targeted antiangiogenic drug delivery for glioblastoma.Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis.Preliminary experience with personalized and targeted therapy for pediatric brain tumors.Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts.
P2860
Q26824557-6B836EEE-AB05-4B71-86CB-55A48FA50A7EQ26853308-61F7308D-632F-47A5-8CEF-251A48035DECQ28082908-CF5079E2-0048-4AFA-895A-046F73E6B85EQ34631627-171E4068-982B-4B3E-A32C-17A30DF3DA90Q34669369-6E3E04BE-D67E-46C5-B997-ACA01B2C3CADQ34837779-0E4F6448-E102-4CDA-A146-8B4E45914410Q35184830-2ED69C23-FE23-41DF-9A58-85C40B5B9C87Q35327883-7909DBCD-9D4B-4133-9AF9-9FB1C4E44847Q35815291-2D388409-AA0E-43D9-98BB-6383B9D533ECQ35914535-1EF66D5D-EA40-4B23-9379-2D8F014A01F3Q36101999-EF03268C-688C-4744-A82D-F8B1966594A1Q36308850-49997339-6F92-4E6E-94D2-92C707EF28EFQ36484434-C0D5D463-42FA-45DF-8F43-41FFA047D0D0Q37708428-91C73BA2-80F7-418C-93D0-190624092194Q37850802-7F58788D-3310-4D7F-BD31-F2E776354D58Q37978530-85B95571-677A-4B0B-9B24-4C753E040540Q38040787-DF76E326-2FD3-4983-9666-05A185C26586Q38539386-B835F97E-F52C-4050-97BD-06DD25B438F8Q38967004-40A989AF-57F7-4CD0-96E5-AF1B81C272F9Q39581577-FE6441A4-C830-47E0-AEC0-1A864E6ABB5AQ44821537-BD582447-C8E9-4227-84D5-A75B2B6796F1Q45259300-E789D1B0-8601-4552-8C6F-AD62524B8745Q47164644-F4BC5490-FBAC-4218-BDCD-FEB0ED34A225Q47736401-A84B7C86-33B6-4184-8B5E-73B40BABCA4EQ48379843-9E3E9F41-C8DD-4651-899F-E790716A7442Q48785864-5F8AE6FA-D367-4E6D-9D7A-0665C2E54C26Q55461776-0A30A7EA-7ED1-4C39-9248-1D1F73BB38DEQ55462737-977E61C1-83FE-402E-87F0-09F41C89C3F0
P2860
Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Effects of bevacizumab plus ir ...... ew and survival-gain analysis.
@ast
Effects of bevacizumab plus ir ...... ew and survival-gain analysis.
@en
type
label
Effects of bevacizumab plus ir ...... ew and survival-gain analysis.
@ast
Effects of bevacizumab plus ir ...... ew and survival-gain analysis.
@en
prefLabel
Effects of bevacizumab plus ir ...... ew and survival-gain analysis.
@ast
Effects of bevacizumab plus ir ...... ew and survival-gain analysis.
@en
P2093
P2860
P921
P356
P1433
P1476
Effects of bevacizumab plus ir ...... ew and survival-gain analysis.
@en
P2093
Johannes Ea Wolff
Juxiang Chen
Yicheng Lu
P2860
P2888
P356
10.1186/1471-2407-10-252
P407
P5008
P577
2010-06-02T00:00:00Z
P5875
P6179
1023564023